Phantom Neuro Advances Phantom X Neuroprosthetic System Into First-in-Human Trial in Australia

According to a recent LinkedIn post from Phantom Neuro, the company has received approval in Australia for CYBORG, its first-in-human clinical study of the Phantom X neuroprosthetic system. The trial is expected to enroll up to 10 adult upper limb amputees in Melbourne, with surgeries at Cabrini Health and prosthetic care and rehabilitation from local partners.

The post highlights Phantom Neuro’s focus on enabling prosthetic hands and robotic devices to operate as intuitive extensions of the human body, aligning the CYBORG study with broader neurotechnology, human–machine interface, AI, and robotics themes. For investors, the move into human clinical testing may represent a key de-risking step for the underlying technology, potentially supporting future regulatory pathways, partnership opportunities with prosthetics providers, and long-term commercialization prospects in the advanced prosthetics market.